Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) EBT: 2023-2025

Historic EBT for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Sep 2025 value amounting to -$19.7 million.

  • Day One Biopharmaceuticals' EBT fell 156.33% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$145.2 million, marking a year-over-year increase of 24.66%. This contributed to the annual value of -$197.6 million for FY2024, which is 4.60% down from last year.
  • Day One Biopharmaceuticals' EBT amounted to -$19.7 million in Q3 2025, which was up 35.02% from -$30.3 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year EBT high stood at $35.0 million for Q3 2024, and its period low was -$110.8 million during Q2 2024.
  • For the 3-year period, Day One Biopharmaceuticals' EBT averaged around -$42.7 million, with its median value being -$44.3 million (2023).
  • Over the last 5 years, Day One Biopharmaceuticals' EBT had its largest YoY gain of 175.75% in 2024, and its largest YoY loss of 161.49% in 2024.
  • Day One Biopharmaceuticals' EBT (Quarterly) stood at -$54.5 million in 2023, then dropped by 8.78% to -$59.3 million in 2024, then plummeted by 156.33% to -$19.7 million in 2025.
  • Its EBT stands at -$19.7 million for Q3 2025, versus -$30.3 million for Q2 2025 and -$36.0 million for Q1 2025.